2 research outputs found
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
This publication is based upon work from COST Action Gene Editing
for the treatment of Human Diseases, CA21113 (https://www.
genehumdi.eu) supported by COST (European Cooperation of Science and Technology). The study was also supported by the ConsejerÃa de Universidad, Investigación e Innovación under Plan Andaluz
de Investigación, Desarrollo e Innovación (PAIDI 2020) (ProyExcel_00875) de la Junta de AndalucÃa, and by ConsejerÃa de Salud y familia de la Junta de AndalucÃa/FEDER (PECART-0027-2020), K.B. held
Nicolas Monardes contract from ConsejerÃa de Salud y Consumo
de la Junta de AndalucÃa.The European Cooperation in Science and Technology (COST)
is an intergovernmental organization dedicated to funding and
coordinating scientific and technological research in Europe,
fostering collaboration among researchers and institutions
across countries. Recently, COST Action funded the "Genome
Editing to treat Human Diseases" (GenE-HumDi) network,
uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech
firms, and patient advocacy groups. GenE-HumDi’s primary
objective is to expedite the application of genome editing for
therapeutic purposes in treating human diseases. To achieve
this goal, GenE-HumDi is organized in several working groups,
each focusing on specific aspects. These groups aim to enhance
genome editing technologies, assess delivery systems, address
safety concerns, promote clinical translation, and develop regulatory guidelines. The network seeks to establish standard
procedures and guidelines for these areas to standardize scientific practices and facilitate knowledge sharing. Furthermore,
GenE-HumDi aims to communicate its findings to the public
in accessible yet rigorous language, emphasizing genome editing’s potential to revolutionize the treatment of many human
diseases. The inaugural GenE-HumDi meeting, held in Granada, Spain, in March 2023, featured presentations from experts
in the field, discussing recent breakthroughs in delivery
methods, safety measures, clinical translation, and regulatory
aspects related to gene editing.COST (European Cooperation of Science and Technology)ConsejerÃa de Universidad, Investigación e Innovación, Junta de AndalucÃa PAIDI 2020, ProyExcel_00875Junta de Andalucia/FEDER (PECART-0027-2020)ConsejerÃa de Salud y Consumo
de la Junta de AndalucÃ
Progress and harmonization of gene editing to treat human diseases: Proceeding of COST Action CA21113 GenE-HumDi
The European Cooperation in Science and Technology (COST) is an intergovernmental organization dedicated to funding and coordinating scientific and technological research in Europe, fostering collaboration among researchers and institutions across countries. Recently, COST Action funded the "Genome Editing to treat Human Diseases" (GenE-HumDi) network, uniting various stakeholders such as pharmaceutical companies, academic institutions, regulatory agencies, biotech firms, and patient advocacy groups. GenE-HumDi's primary objective is to expedite the application of genome editing for therapeutic purposes in treating human diseases. To achieve this goal, GenE-HumDi is organized in several working groups, each focusing on specific aspects. These groups aim to enhance genome editing technologies, assess delivery systems, address safety concerns, promote clinical translation, and develop regulatory guidelines. The network seeks to establish standard procedures and guidelines for these areas to standardize scientific practices and facilitate knowledge sharing. Furthermore, GenE-HumDi aims to communicate its findings to the public in accessible yet rigorous language, emphasizing genome editing's potential to revolutionize the treatment of many human diseases. The inaugural GenE-HumDi meeting, held in Granada, Spain, in March 2023, featured presentations from experts in the field, discussing recent breakthroughs in delivery methods, safety measures, clinical translation, and regulatory aspects related to gene editing